Over the past year or so, the pharmaceutical industry has tried to leave the patent cliff behind and persuade investors to focus on their product pipelines. But sorting out which drug makers are most likely to capitalize as they grapple with generic competition and seek…
Read More
Latest in AstraZeneca Archives - Access International Patent
More Articles
LOS ANGELES (MarketWatch) — Drug makers face another patent cliff in which the industry will lose roughly $65 billion in revenue through the end of 2019, according to a research firm’s report. But the 376-page study from London-based GlobalData says this cliff will be more…
Read More